Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.
2.

Does prior antidepressant treatment of major depression impact brain function during current treatment?

Hunter AM, Cook IA, Leuchter AF.

Eur Neuropsychopharmacol. 2012 Oct;22(10):711-20. doi: 10.1016/j.euroneuro.2012.02.005. Epub 2012 Mar 23.

PMID:
22445212
3.

Early changes in prefrontal activity characterize clinical responders to antidepressants.

Cook IA, Leuchter AF, Morgan M, Witte E, Stubbeman WF, Abrams M, Rosenberg S, Uijtdehaage SH.

Neuropsychopharmacology. 2002 Jul;27(1):120-31.

4.

Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder.

Bares M, Brunovsky M, Kopecek M, Novak T, Stopkova P, Kozeny J, Sos P, Krajca V, Höschl C.

Eur Psychiatry. 2008 Aug;23(5):350-5. doi: 10.1016/j.eurpsy.2008.03.001. Epub 2008 May 2.

PMID:
18450430
5.

QEEG Theta Cordance in the Prediction of Treatment Outcome to Prefrontal Repetitive Transcranial Magnetic Stimulation or Venlafaxine ER in Patients With Major Depressive Disorder.

Bares M, Brunovsky M, Novak T, Kopecek M, Stopkova P, Sos P, Höschl C.

Clin EEG Neurosci. 2015 Apr;46(2):73-80. doi: 10.1177/1550059413520442. Epub 2014 Apr 7.

PMID:
24711613
6.

Changes in brain function of depressed subjects during treatment with placebo.

Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M.

Am J Psychiatry. 2002 Jan;159(1):122-9.

PMID:
11772700
7.

Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder.

Korb AS, Hunter AM, Cook IA, Leuchter AF.

Psychiatry Res. 2011 Jun 30;192(3):188-94. doi: 10.1016/j.pscychresns.2010.12.007. Epub 2011 May 4.

8.

Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression.

Hunter AM, Ravikumar S, Cook IA, Leuchter AF.

Acta Psychiatr Scand. 2009 Apr;119(4):266-73. doi: 10.1111/j.1600-0447.2008.01305.x. Epub 2008 Dec 9.

PMID:
19077131
9.

Predictors of improved mood over time in clinical trials for major depression.

Marie-Mitchell A, Leuchter AF, Chou CP, James Gauderman W, Azen SP.

Psychiatry Res. 2004 Jun 30;127(1-2):73-84.

PMID:
15261707
10.

Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.

Hunter AM, Muthén BO, Cook IA, Leuchter AF.

J Psychiatr Res. 2010 Jan;44(2):90-8. doi: 10.1016/j.jpsychires.2009.06.006. Epub 2009 Jul 24.

11.

Midline and right frontal brain function as a physiologic biomarker of remission in major depression.

Cook IA, Hunter AM, Abrams M, Siegman B, Leuchter AF.

Psychiatry Res. 2009 Nov 30;174(2):152-7. doi: 10.1016/j.pscychresns.2009.04.011. Epub 2009 Oct 22.

12.

Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression.

Leuchter AF, Morgan M, Cook IA, Dunkin J, Abrams M, Witte E.

Psychopharmacology (Berl). 2004 Dec;177(1-2):15-22. Epub 2004 Jul 14.

PMID:
15252704
13.

Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo.

Hunter AM, Leuchter AF, Morgan ML, Cook IA, Abrams M, Siegman B, DeBrota DJ, Potter WZ.

Neuropsychopharmacology. 2005 Apr;30(4):792-9.

14.

Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.

Kornstein SG, Pedersen RD, Holland PJ, Nemeroff CB, Rothschild AJ, Thase ME, Trivedi MH, Ninan PT, Keller MB.

J Clin Psychiatry. 2014 Jan;75(1):62-8. doi: 10.4088/JCP.12m07841.

PMID:
24345717
15.
16.

The brain tells: early signs of depression recovery.

[No authors listed]

Harv Ment Health Lett. 2002 Nov;19(5):6. No abstract available.

PMID:
12453746
17.

Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.

Sheehan DV, Nemeroff CB, Thase ME, Entsuah R; EPIC 016 Study Group.

Int Clin Psychopharmacol. 2009 Mar;24(2):61-86. doi: 10.1097/YIC.0b013e32831980f2.

PMID:
19238088
18.

Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder.

Judd LL, Rapaport MH, Yonkers KA, Rush AJ, Frank E, Thase ME, Kupfer DJ, Plewes JM, Schettler PJ, Tollefson G.

Am J Psychiatry. 2004 Oct;161(10):1864-71.

PMID:
15465984
19.

Cordance derived from REM sleep EEG as a biomarker for treatment response in depression--a naturalistic study after antidepressant medication.

Adamczyk M, Gazea M, Wollweber B, Holsboer F, Dresler M, Steiger A, Pawlowski M.

J Psychiatr Res. 2015 Apr;63:97-104. doi: 10.1016/j.jpsychires.2015.02.007. Epub 2015 Feb 19.

PMID:
25772006
20.

Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment.

Hunter AM, Leuchter AF, Cook IA, Abrams M.

Acta Psychiatr Scand. 2010 Dec;122(6):461-9. doi: 10.1111/j.1600-0447.2010.01560.x.

PMID:
20384600

Supplemental Content

Support Center